CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.

Oncol Res Treat · 2025 · PMC12237281 · PMID 40418924

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a marginal trendno p-value reported

With regard to the ACTS Benefit, even a marginal trend toward LMWH was detected [ 20 ].

also in 185 other papers

did not reach statistical significanceno p-value reported

In the prespecified subgroup analysis, the ACTS Burdens score showed a consistent relative benefit for rivaroxaban but did not reach statistical significance in CAT.

also in 39,124 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.